Technetium-99m chelator-free radiolabeling of specific glutamine tumor imaging nanoprobe: in vitro and in vivo evaluations
Nowadays, molecular imaging radiopharmaceuticals', nanoparticles', and/or small-molecule biomarkers' applications are increasing rapidly worldwide. Thus, researchers focus on providing the novel, safe, and cost-effective ones. In the present experiment, technetium-99m ( Tc)-labeled PE...
Saved in:
Published in: | International journal of nanomedicine Vol. 13; pp. 4671 - 4683 |
---|---|
Main Authors: | , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
New Zealand
Dove Medical Press Limited
01-01-2018
Taylor & Francis Ltd Dove Medical Press |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Nowadays, molecular imaging radiopharmaceuticals', nanoparticles', and/or small-molecule biomarkers' applications are increasing rapidly worldwide. Thus, researchers focus on providing the novel, safe, and cost-effective ones.
In the present experiment, technetium-99m (
Tc)-labeled PEG-citrate dendrimer-G
conjugated with glutamine (nanoconjugate) was designed and assessed as a novel tumor imaging probe both in vitro and in vivo. Nanoconjugate was synthesized and the synthesis was confirmed by Fourier transform infrared, proton nuclear magnetic resonance, liquid chromatography-mass spectrometry, dynamic light scattering, and static light scattering techniques. The toxicity was assessed by XTT and apoptosis and necrosis methods.
Radiochemical purity indicates that the anionic dendrimer has a very high potential to complex formation with
Tc and is also very stable in the human serum in different times. Results from the imaging procedures showed potential ability of nanoconjugates to detect tumor site.
Suitable features of the anionic dendrimer show that it is a promising agent to improve nanoradiopharmaceuticals. |
---|---|
ISSN: | 1178-2013 1176-9114 1178-2013 |
DOI: | 10.2147/IJN.S157426 |